APA (7th ed.) Citation

S, K., J, T., T, M., T, S., S, H., S, K., . . . A, H. (2026). Conversion surgery following trastuzumab and docetaxel combination therapy for unresectable HER2-positive parotid gland cancer. Auris, nasus, larynx, 53(3), 328. https://doi.org/10.1016/j.anl.2026.03.001

Chicago Style (17th ed.) Citation

S, Kano, Taguchi J, Maeda T, Suzuki T, Hamada S, Kato S, Saito A, Shimizu Y, and Homma A. "Conversion Surgery Following Trastuzumab and Docetaxel Combination Therapy for Unresectable HER2-positive Parotid Gland Cancer." Auris, Nasus, Larynx 53, no. 3 (2026): 328. https://doi.org/10.1016/j.anl.2026.03.001.

MLA (9th ed.) Citation

S, Kano, et al. "Conversion Surgery Following Trastuzumab and Docetaxel Combination Therapy for Unresectable HER2-positive Parotid Gland Cancer." Auris, Nasus, Larynx, vol. 53, no. 3, 2026, p. 328, https://doi.org/10.1016/j.anl.2026.03.001.